Startups Amass University IP to Develop Stem Cell ‘Reprogramming’ Tools for Rx Use

The two companies, Cascade LifeSciences and Fate Therapeutics, are developing stem cell reprogramming technologies that they believe have greater commercial potential for therapeutic use than recently publicized methods for creating “induced” pluripotent stem cells because they don’t use retroviral vectors or oncogenes.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.